55 related articles for article (PubMed ID: 30677005)
1. Loose Regulatory Standards Portend a New Era of Imprecision Oncology.
Khaki AR
Cancer Invest; 2021 Feb; 39(2):120-123. PubMed ID: 33290099
[TBL] [Abstract][Full Text] [Related]
2. First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer.
Mullard A
Nat Rev Drug Discov; 2024 Jun; 23(6):410. PubMed ID: 38671056
[No Abstract] [Full Text] [Related]
3. New drug approvals for prostate cancer.
Tannock IF
Clin Adv Hematol Oncol; 2024 Jun; 22(5):245-246. PubMed ID: 38805317
[No Abstract] [Full Text] [Related]
4. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
Yu YD; Kim TJ
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
[TBL] [Abstract][Full Text] [Related]
5. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
[No Abstract] [Full Text] [Related]
6. Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
Beaver JA; Kluetz PG; Pazdur R
N Engl J Med; 2018 Jun; 378(26):2458-2460. PubMed ID: 29949489
[No Abstract] [Full Text] [Related]
7. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
9. Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
Pilon D; Ellis LA; Xiao Y; Behl AS; Lefebvre P
Am J Ther; 2019; 26(3):e422-e424. PubMed ID: 30677005
[No Abstract] [Full Text] [Related]
10. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
11. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
